new directors can only be a positive. they both appear to have substantial medical and financial muscle. that's what we need as things get very interesting and next trials (both HCV and HIV) are very very important. the J&J saturation is a benefit given it is a reputad company, household name and there is an obvious connection, however, they will be looking at all comers. it may not be a big gun they end up with but one of the existing HCV players would seem to make sense. we don't necessarily want to be viewed as a bolt-on, but they may end up being the case.
GL to all.
BIT Price at posting:
15.0¢ Sentiment: LT Buy Disclosure: Held
